Last reviewed · How we verify
Placebo teriparatide — Competitive Intelligence Brief
marketed
Endocrinology
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo teriparatide (Placebo teriparatide) — University of California, San Francisco. Placebo teriparatide is an inactive control formulation used in clinical trials to compare against active teriparatide treatment.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo teriparatide TARGET | Placebo teriparatide | University of California, San Francisco | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo teriparatide CI watch — RSS
- Placebo teriparatide CI watch — Atom
- Placebo teriparatide CI watch — JSON
- Placebo teriparatide alone — RSS
Cite this brief
Drug Landscape (2026). Placebo teriparatide — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-teriparatide. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab